Everything below concerns Cardarine. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-29. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
According to the International Programme on Chemical Safety (IPCS) and the U.S. Food and Drug Administration (FDA), amphetamine is contraindicated in people with a history of drug abuse, cardiovascular disease, severe agitation, or severe anxiety. It is also contraindicated in individuals with advanced arteriosclerosis (hardening of the arteries), glaucoma (increased eye pressure), hyperthyroidism (excessive production of thyroid hormone), or moderate to severe hypertension. These agencies indicate that people who have experienced allergic reactions to other stimulants or who are taking monoamine oxidase inhibitors (MAOIs) should not take amphetamine, although safe concurrent use of amphetamine and monoamine oxidase inhibitors has been documented. These agencies also state that anyone with anorexia nervosa, bipolar disorder, depression, hypertension, liver or kidney problems, mania, psychosis, Raynaud's phenomenon, seizures, thyroid problems, tics, or Tourette syndrome should monitor their symptoms while taking amphetamine. Evidence from human studies indicates that therapeutic amphetamine use does not cause developmental abnormalities in the fetus or newborns (i.e., it is not a human teratogen), but amphetamine abuse does pose risks to the fetus. Amphetamine has also been shown to pass into breast milk, so the IPCS and the FDA advise mothers to avoid breastfeeding when using it. Due to the potential for reversible growth impairments, the FDA advises monitoring the height and weight of children and adolescents prescribed an amphetamine pharmaceutical.
A more plausible alternative for the evolutionary origins of this system is through constructive neutral evolution, where the order of steps is reversed, with the gratuitous capacity for editing preceding the "defect".
In 2005, Sean Kinney came up with the idea of doing a benefit concert for the victims of the tsunami disaster that struck South Asia in 2004. Kinney made calls to his former bandmates, as well as friends in the music community, such as former Alice in Chains manager Susan Silver. Kinney was surprised by the enthusiastic response to his idea. On February 18, 2005, Jerry Cantrell, Mike Inez, and Sean Kinney reunited to perform for the first time in nine years at K-Rock Tsunami Continued Care Relief Concert in Seattle. The band featured Damageplan vocalist Pat Lachman, as well as other special guests including Maynard James Keenan of Tool, Wes Scantlin of Puddle of Mudd and Ann Wilson of Heart. A few months after that experience, the band called Susan Silver and Cantrell's manager Bill Siddons and said they wanted to tour as Alice in Chains again. Alice in Chains was approached by the producers of the CBS reality show Rock Star about being featured on its second season, but the band turned the offer down. In the show, aspiring singers competed to become the lead vocalist of a featured group. On March 10, 2006, the surviving members performed at VH1's Decades Rock Live! concert, honoring fellow Seattle musicians Ann and Nancy Wilson of Heart. They played "Would?" with vocalist Phil Anselmo of Pantera and Down and bass player Duff McKagan of Guns N' Roses and Velvet Revolver, and at the end of the performance Cantrell dedicated the show to Layne Staley and the late Pantera and Damageplan guitarist Dimebag Darrell.
After the Colombian government dismantled many of the drug cartels that appeared in the country during the 1980s, left-wing guerrilla groups, and right-wing paramilitary organizations resumed some of their drug trafficking activities. They resorted to extortion and kidnapping for their financing: activities which led to a loss of support from the local population. These funds helped finance paramilitaries and guerrillas, allowing these organizations to buy weapons which were then sometimes used to attack military and civilian targets. Natural resources were found to be correlated with the conflict, while higher per capita income and public investment were associated with reduced conflict intensity. During the presidency of Álvaro Uribe, the government applied more military pressure on the FARC and other outlawed far-left groups. After the offensive, many security indicators improved. As part of a controversial peace process, the AUC (a right-wing paramilitary group) as a formal organization had ceased to function. Colombia achieved a considerable reduction in cocaine production, leading White House drug czar R. Gil Kerlikowske to announce that Colombia was no longer the world's biggest producer of cocaine. In February 2008, millions of Colombians demonstrated against the FARC and other outlawed groups. The Colombian Ministry of Defense reported 19,504 deserters from the FARC between August 2002 and their collective demobilization in 2017, peaking in the year 2008. During these years, the military forces of the Republic of Colombia were strengthened.
Instead, the company offered to provide the medication free through its patient access program for hardship cases, though this option was described as much more restrictive. Oncologists criticized the decision as unprecedented, with Dr. Carmen de Ramon Ortiz of Geneva University Hospital noting that about 20% of follicular lymphoma patients require intensive treatment and that Lunsumio represents "a very innovative immunotherapy that stimulates the immune system, leading to high remission rates." Industry experts characterized the withdrawal as a form of healthcare rationing and a "canary in the coal mine," noting that only half of EU-approved medications are available in Switzerland. Some experts suggested the withdrawal reflected broader pressures from potential U.S. pricing reforms and trade uncertainties that could affect Roche's largest market, including potential tariff increases on pharmaceutical exports from 10% to up to 31%. The case was viewed by analysts as a potential precedent-setting "regulatory showdown" that could influence pharmaceutical pricing negotiations across the industry, particularly for rare disease treatments affecting small patient populations.
Sources: en.wikipedia.org
One of the best examples of the special features caused by DNA encoding is the synthesis of the self-assembling library introduced by Mlecco et al. First, two sublibraries are synthesized. In one of the sublibraries BBs are attached to the 5’ end of an oligonucleotide containing a dimerization domain followed by the codes of the BBs. In the other sublibrary the BBs are attached to the 3’ end of the oligonucleotides also containing a dimerization domain and the codes of another set of BBs. The two sublibraries are mixed in equimolar quantities, heated to 70 °C then allowed to cool to room temperature, heterodimerize and form the self-assembling combinatorial library. One member of such two pharmacophore library is shown in the figure. In affinity screening, the two BBs of the pharmacophore may interact with the two adjacent binding sites of the target protein.
=== Frequency of use === PCP began to emerge as a recreational drug in major cities in the US in the 1960s. In 1978, People magazine and Mike Wallace of the TV news program 60 Minutes called PCP the country's "number one drug problem". Although recreational use of the drug had always been relatively low, it began declining significantly in the 1980s. In surveys, the number of high school students admitting to trying PCP at least once fell from 13% in 1979 to less than 3% in 1990.
Samidorphan (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name) is an opioid antagonist that in the form of olanzapine/samidorphan (sold as Lybalvi) is used in the treatment of schizophrenia and bipolar disorder. Samidorphan reduces the weight gain associated with olanzapine. Samidorphan is taken by mouth. Samidorphan was under development as a standalone medication for various indications but has been discontinued. Buprenorphine/samidorphan for the treatment of major depressive disorder was rejected by the US Food and Drug Administration (FDA) due to insufficient evidence of effectiveness, but remains in preregistration as of September 2021. Development of baclofen/samidorphan has also been discontinued.
== Pathophysiology == The primary characteristic of MASLD is the accumulation of lipids in the liver, largely in the form of triglycerides. However, the mechanisms by which triglycerides accumulate and the reasons that accumulation can lead to liver dysfunction are complex and incompletely understood. MASLD can include steatosis along with varied signs of liver injury: either lobular or portal inflammation (a form of liver injury) or ballooning degeneration. Similarly, MASH can include histological features such as portal inflammation, polymorphonuclear cell infiltrates, Mallory bodies, apoptotic bodies, clear vacuolated nuclei, microvesicular steatosis, megamitochondria, and perisinusoidal fibrosis. Hepatocyte death via apoptosis or necroptosis is increased in MASH compared with simple steatosis, and inflammation is a hallmark of MASH. The degree of inflammation can be correlated to the number of inflammatory foci. Various definitions exist for an inflammatory focus, but one defines it as the presence of more than four mononuclear cells in proximity within the hepatic parenchyma. One debated mechanism proposes that hepatic steatosis progresses to steatosis with inflammation following some further injury, or second hit. Oxidative stress, hormonal imbalances, and mitochondrial abnormalities are potential causes of this "second hit" phenomenon. A further nutrigenomics model named multiple hit extends the second hit model, suggesting that multiple disease biomarkers and factors such as genes and nutrition influence MASLD and MASH progression.
==== Gastrointestinal bleeding ==== The most common cause of iron deficiency anemia in men and post-menopausal women is gastrointestinal bleeding. There are many sources of gastrointestinal tract bleeding, including the stomach, esophagus, small intestine, and the large intestine (colon). Gastrointestinal bleeding can result from regular use of some medications, such as non-steroidal anti-inflammatory drugs (e.g. aspirin), as well as antiplatelets such as clopidogrel and anticoagulants such as warfarin; however, these are required in some patients, especially those with states causing a tendency to form blood clots. Colon cancer, which typically occurs in older individuals, is another potential cause of gastrointestinal bleeding. In addition, some bleeding disorders, such as von Willebrand disease and polycythemia vera, can cause gastrointestinal bleeding.
Sources: en.wikipedia.org
The US and the USSR sent animals into space to determine the safety of the environment before sending the first humans. The USSR used dogs for this purpose, and the US used monkeys and apes. The first mammal in space was Albert II, a rhesus monkey launched by the US on a sub-orbital flight on June 14, 1949, who died on landing due to a parachute malfunction. The USSR sent the dog Laika into orbit on Sputnik 2, the second satellite launched, on November 3, 1957, for an intended ten-day flight. They did not yet have the technology to return Laika safely to Earth, and the government reported Laika died when the oxygen ran out, but in October 2002 her true cause of death was reported as stress and overheating on the fourth orbit due to failure of the air conditioning system. At a Moscow press conference in 1998 Oleg Gazenko, a senior Soviet scientist involved in the project, stated "The more time passes, the more I'm sorry about it. We did not learn enough from the mission to justify the death of the dog...".
According to the 2025 Global Organized Crime Index, Pakistan had a criminality score of 6.32 out of 10, ranking 45th among 193 countries, and a resilience score ranking 131st among 193 countries, with the latter measuring the country's capacity to withstand and respond to organized crime. According to the Federal Investigation Agency's annual report, the agency received more than 73,000 cybercrime complaints in 2024, of which 1,604 were registered as cases, with financial fraud accounting for nearly half of all complaints. In 2025, the National Cyber Crimes Investigation Agency estimated that cybercrime had increased by about 35% compared with the previous year. A 2025 survey conducted on behalf of Visa Inc. found that 55% of respondents in Pakistan had fallen victim to an online scam in 2024, while 20% reported having been victims more than once. Pakistan scored 27 out of 100 on the Corruption Perceptions Index in 2024, ranking 135th out of 180 countries in the assessment of perceived public-sector corruption.
Carefully research the demand for their potential new product before spending an outlay of company funds. Obtain a patent on the new medicine preventing other companies from producing that medicine for a certain allocation of time. The Inverse Benefit Law describes the relationship between a drug's therapeutic benefits and the socioeconomic status (overall health risk/need) of the population undergoing treatment. The law states that the therapeutic benefit conferred by medical interventions upon a population is inversely proportional to its incidence of disease or socioeconomic need. When designing drugs, the placebo effect must be considered to assess the drug's true therapeutic value. Drug development uses techniques from medicinal chemistry to chemically design drugs. This overlaps with the biological approach of finding targets and physiological effects.
The scanning mechanism of Initiation starts when the PIC binds the 5′ end of the mRNA. Scanning is stimulated by Dhx29 and Ddx3/Ded1 and eIF4 proteins. The Dhx29 and Ddx3/Ded1 are DEAD-box helicases that help to unwind any secondary mRNA structure which could hinder scanning. The scanning of an mRNA continues until the first AUG codon on the mRNA is reached, this is known as the "First AUG Rule". While exceptions to the "First AUG Rule" exist, most exceptions take place at a second AUG codon that is located 3 to 5 nucleotides downstream from the first AUG, or within 10 nucleotides from the 5′ end of the mRNA. At the AUG codon a Methionine tRNA anticodon is recognized by mRNA codon. Upon base pairing to the start codon the eIF5 in the PIC helps to hydrolyze a guanosine triphosphate (GTP) bound to the eIF2. This leads to the a structural rearrangement that commits the PIC to binding to the large ribosomal subunit (60S) and forming the ribosomal complex (80S). Once the 80S ribosome complex is formed then the elongation phase of translation starts. The first start codon closest to the 5′ end of the strand is not always recognized if it is not contained in a Kozak-like sequence. Lmx1b is an example of a gene with a weak Kozak consensus sequence. For initiation of translation from such a site, other features are required in the mRNA sequence in order for the ribosome to recognize the initiation codon. Exceptions to the first AUG rule may occur if it is not contained in a Kozak-like sequence.
==== Ethiopia ==== Approximately 30% of the Ethiopian population carry an extra copy of the gene CYP2D6, and are classified as codeine ultrametabolizers. These individuals metabolize codeine to morphine at a dangerously fast rate, leading to adverse events and potentially death. As a consequence the Ethiopian Food, Medicine and Health Care Administration and Control Authority has entirely banned the use of codeine as unsafe for the general population.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.